Immunovant Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Immunovant han disminuido a una tasa media anual de -36.4%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente.

Información clave

-36.4%

Tasa de crecimiento de los beneficios

-6.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera	-35.8%
Margen neto	n/a
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Immunovant. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:IMVT Ingresos, gastos y beneficios (USD Millions)
Fecha	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	-243	55	199
30 Sep 23	-255	53	193
30 Jun 23	-245	51	182
31 Mar 23	-211	48	160
31 Dec 22	-199	51	140
30 Sep 22	-177	51	128
30 Jun 22	-167	55	112
31 Mar 22	-157	54	102
31 Dec 21	-138	49	88
30 Sep 21	-128	48	80
30 Jun 21	-111	41	70
31 Mar 21	-107	40	69
31 Dec 20	-100	33	64
30 Sep 20	-79	29	48
30 Jun 20	-73	24	46
31 Mar 20	-66	16	48
31 Dec 19	-55	13	42
30 Sep 19	-52	8	44
30 Jun 19	-44	4	40
31 Mar 19	-29	3	26

Ingresos de calidad: IMVT actualmente no es rentable.

Margen de beneficios creciente: IMVT actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: IMVT no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 36.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de IMVT en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: IMVT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: IMVT tiene una rentabilidad financiera negativa (-35.84%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Immunovant Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Immunovant, Inc. to Report Q4, 2022 Results on Jun 08, 2022

Recent updates

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Chief Financial Officer recently sold US$52k worth of stock

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 17, 2022

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth Index

Immunovant, Inc. Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease

Immunovant, Inc. to Report Q4, 2022 Results on Jun 08, 2022

Price target decreased to US$10.78

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Price target decreased to US$11.25

Chief Medical Officer recently sold US$222k worth of stock

Price target decreased to US$12.25

Immunovant, Inc. Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

Independent Director recently bought US$150k worth of stock

Independent Director recently bought US$54k worth of stock

Price target decreased to US$19.86

Immunovant, Inc. announced that it has received $199.999993 million in funding

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth-Defensive Index

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Price target decreased to US$31.88

Immunovant EPS beats by $0.04

The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New 90-day low: US$15.94

Pomerantz Law Firm Announces Filing of Class Action Against Immunovant, Inc

New 90-day low: US$24.10

Price target lowered to US$43.00

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

New 90-day low: US$41.62

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Immunovant, Inc. Appoints Rita Jain as Chief Medical Officer

Desglose de ingresos y gastos
Beta